← All trials
NCT06378684
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 10, 2023
- Primary completion
- Dec 23, 2023
- Completion date
- Jan 13, 2024
- First posted
- Apr 22, 2024
- Last posted
- Apr 22, 2024
- Enrollment
- 48
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- JW PharmaceuticalLead sponsor
- Yonsei UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.